PE20050861A1 - DERIVATIVES OF QUATERNARY AMMONIUM CYCLIC SALTS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR - Google Patents

DERIVATIVES OF QUATERNARY AMMONIUM CYCLIC SALTS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR

Info

Publication number
PE20050861A1
PE20050861A1 PE2004001184A PE2004001184A PE20050861A1 PE 20050861 A1 PE20050861 A1 PE 20050861A1 PE 2004001184 A PE2004001184 A PE 2004001184A PE 2004001184 A PE2004001184 A PE 2004001184A PE 20050861 A1 PE20050861 A1 PE 20050861A1
Authority
PE
Peru
Prior art keywords
phenyl
alkyl
cycloalkyl
methyl
antagonists
Prior art date
Application number
PE2004001184A
Other languages
Spanish (es)
Inventor
Jacob Busch-Petersen
Jian Jin
Ralph A Rivero
Dongchuan Shi
Yonghui Wang
Michael Lee Moore
Feng Wang
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20050861A1 publication Critical patent/PE20050861A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DERIVADOS DE SALES CICLICAS DE AMONIO CUATERNARIO DE FORMULA I DONDE n ES 0-1; CUANDO X ES N, O, Y NO EXISTE; CUANDO Y ES N, O, X NO EXISTE; T ES SO2, CO; Z- ES HALO, CF3COO-, MESILATO,TOSILATO, ENTRE OTROS; R1 ES ALQUILO C1-C6 RAMIFICADO O NO, CICLOALQUILO C3-C8, ALQUENILO C3-C8, FENILO SUSTITUIDO O NO, ENTRE OTROS; R2 ES ALQUILO C1-C8 RAMIFICADO O NO, CICLOALQUILO C3-C8, FENILO SUSTITUIDO O NO, ENTRE OTROS; R3 ES FENILO, FENIL-ALQUILO INFERIOR C1-C6, TIOFENILO, FURANILO, ENTRE OTROS; R4 ES ALQUILOC1-C8 RAMIFICADO O NO, CICLOALQUILO C3-C8 O CICLOALQUIL C3-C8-ALQUILO INFERIOR. SON COMPUESTOS PREFERIDOS: TRIFLUOROACETATO DE N-((3S)-1-{[3,4-BIS(METILOXI)FENIL]METIL}-1-METIL-PIPERIDINIOIL)-N-{[(4-{[(2,2,2-TRIFLUOROETIL)SULFONIL]OXI}FENIL)AMINO]CARBONIL}-L-TIROSINAMIDA; TRIFLUOROACETATO DE N-((3S)-1-{[3,4-BIS(METILOXI)FENIL]METIL}-1-METIL-3-PIPERIDINIOIL)-N-({[4-({[3,4-BIS-(METILOXI)FENIL]SULFONIL}OXI)FENIL]AMINO}CARBONIL)-L-TIROSINAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA; DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR MUSCARINICO DE ACETILCOLINA UTILES EN EL TRATAMIENTO DE ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, BRONQUITIS CRONICA, ASMA, FIBROSIS PULMONAR, ENTRE OTROSIT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES DERIVATIVES OF QUATERNARY AMMONIUM CYCLIC SALTS OF FORMULA I WHERE n IS 0-1; WHEN X IS N, O, AND DOES NOT EXIST; WHEN Y IS N, O, X DOES NOT EXIST; T IS SO2, CO; Z- IS HALO, CF3COO-, MESYLATE, TOSYLATE, AMONG OTHERS; R1 IS C1-C6 ALKYL BRANCHED OR NOT, C3-C8 CYCLOALKYL, C3-C8 ALKYL, SUBSTITUTED PHENYL OR NOT, AMONG OTHERS; R2 IS C1-C8 ALKYL BRANCHED OR NOT, C3-C8 CYCLOALKYL, SUBSTITUTED PHENYL OR NOT, AMONG OTHERS; R3 IS PHENYL, C1-C6 LOWER PHENYL-ALKYL, THIOPHENYL, FURANIL, AMONG OTHERS; R4 IS ALKYLOC1-C8 BRANCHED OR NOT, CYCLOALKYL C3-C8 OR CYCLOALKYL C3-C8-LOWER ALKYL. PREFERRED COMPOUNDS ARE: N - ((3S) -1 - {[3,4-BIS (METHYLOXY) PHENYL] METHYL} -1-METHYL-PIPERIDINIOIL) -N - {[(4 - {[(2,2 , 2-TRIFLUOROETHYL) SULFONIL] OXY} PHENYL) AMINO] CARBONYL} -L-TYROSINAMIDE; N - ((3S) -1 - {[3,4-BIS (METHYLOXY) PHENYL] METHYL} -1-METHYL-3-PIPERIDINIOYL) -N - ({[4 - ({[3,4-BIS - (METILOXI) PHENYL] SULFONIL} OXY) PHENYL] AMINO} CARBONYL) -L-TYROSINAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION; SUCH COMPOUNDS ARE ANTAGONISTS OF THE MUSCARINAL ACETYLCHOLINE RECEPTOR, USEFUL IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CHRONIC BRONCHITIS, ASTHMA, PULMONARY FIBROSIS, AMONG OTHERS

PE2004001184A 2003-12-03 2004-12-01 DERIVATIVES OF QUATERNARY AMMONIUM CYCLIC SALTS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR PE20050861A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52676603P 2003-12-03 2003-12-03

Publications (1)

Publication Number Publication Date
PE20050861A1 true PE20050861A1 (en) 2005-12-10

Family

ID=34676649

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001184A PE20050861A1 (en) 2003-12-03 2004-12-01 DERIVATIVES OF QUATERNARY AMMONIUM CYCLIC SALTS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR

Country Status (20)

Country Link
US (1) US20070179180A1 (en)
EP (1) EP1694327A4 (en)
JP (1) JP2007513182A (en)
KR (1) KR20060123414A (en)
CN (1) CN1913895A (en)
AR (1) AR046783A1 (en)
AU (1) AU2004296208A1 (en)
BR (1) BRPI0417343A (en)
CA (1) CA2549273A1 (en)
IL (1) IL176078A0 (en)
IS (1) IS8522A (en)
MA (1) MA28218A1 (en)
MX (1) MXPA06006256A (en)
NO (1) NO20063032L (en)
PE (1) PE20050861A1 (en)
RU (1) RU2006123418A (en)
TW (1) TW200530226A (en)
UY (1) UY28646A1 (en)
WO (1) WO2005055941A2 (en)
ZA (1) ZA200604485B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
OA13270A (en) * 2003-10-17 2007-01-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists.
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2005094251A2 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
WO2005095407A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
TWI363759B (en) 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) * 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
JP2008520579A (en) * 2004-11-15 2008-06-19 グラクソ グループ リミテッド Novel M3 muscarinic acetylcholine receptor antagonist
WO2007016639A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US7767691B2 (en) 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
ES2554646T3 (en) * 2007-02-23 2015-12-22 Theravance Biopharma R&D Ip, Llc Quaternary ammonium diphenylmethyl compounds, useful as muscarinic receptor antagonists
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
UY31637A1 (en) 2008-02-06 2009-08-03 DUE PHARMACOPHORES-MUSCARINIC ANTAGONISTS OF PDE4
UY31635A1 (en) 2008-02-06 2009-08-31 DUE PHARMACOPHORS-MUSCARINIC ANTAGONISTS OF PDE4
AR070563A1 (en) 2008-02-06 2010-04-21 Glaxo Group Ltd COMPOSITE OF A CONDENSED BICYCLE PIRAZOL-PIRIDIN-AMINA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICATION FOR THE TREATMENT OF RESPIRATORY DISEASES.
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482837B1 (en) * 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
WO2001010439A1 (en) * 1999-08-04 2001-02-15 Teijin Limited Cyclic amine ccr3 antagonists
DE10063008A1 (en) * 2000-12-16 2002-06-20 Merck Patent Gmbh carboxamide
DE10201550A1 (en) * 2002-01-17 2003-07-31 Merck Patent Gmbh Phenoxy piperidines

Also Published As

Publication number Publication date
EP1694327A4 (en) 2009-11-25
BRPI0417343A (en) 2007-03-13
CA2549273A1 (en) 2005-06-23
RU2006123418A (en) 2008-01-10
CN1913895A (en) 2007-02-14
AR046783A1 (en) 2005-12-21
IL176078A0 (en) 2006-10-05
US20070179180A1 (en) 2007-08-02
JP2007513182A (en) 2007-05-24
IS8522A (en) 2006-06-26
ZA200604485B (en) 2007-11-28
NO20063032L (en) 2006-08-30
KR20060123414A (en) 2006-12-01
UY28646A1 (en) 2005-06-30
AU2004296208A1 (en) 2005-06-23
TW200530226A (en) 2005-09-16
WO2005055941A2 (en) 2005-06-23
EP1694327A2 (en) 2006-08-30
MXPA06006256A (en) 2006-08-23
WO2005055941A3 (en) 2006-02-16
MA28218A1 (en) 2006-10-02

Similar Documents

Publication Publication Date Title
PE20050861A1 (en) DERIVATIVES OF QUATERNARY AMMONIUM CYCLIC SALTS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR
RU2424240C2 (en) Antibacterial piperidine derivatives
PE20070011A1 (en) PHARMACEUTICAL FORMULATIONS OF HCV PROTEASE INHIBITOR COMPOUNDS OR CATEPSIN
PE20040522A1 (en) DIARYLUREA DERIVATIVES DEPENDENT ON PROTEIN KINASE
DE602004005886D1 (en) DERIVATIVES OF N-ÄPHENYL (ALKYLPIPERIDIN-2-YL) METHYLUBENZAMIDE, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATION IN THERAPEUTICS
RS54580B1 (en) New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders
HRP20130174T1 (en) Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis
EA200702238A1 (en) COMBINATION, METHOD AND COMPOSITION FOR CANCER TREATMENT
AR072471A1 (en) BENZOXACINES AND BENZOTIACINES WITH US INHIBITING ACTIVITY, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES IN PAIN TREATMENT.
PE20040644A1 (en) NEW DERIVATIVES OF QUINUCLIDINE-AMINE
TW200619199A (en) 3-carbamoyl-2-pyridone derivatives
TW200700416A (en) 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
AR037460A1 (en) HYDROXYETHYLENE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURE FOR PREPARATION
PE20041079A1 (en) ACETYL-2-HYDROXY-1,3-DIAMINOALKANES
PE20000263A1 (en) CYCLIC DERIVATIVES N-ACILO OF AMINE
PE20050142A1 (en) BENZAMIDE 2-HYDROXY-3-DIAMINOALKANES
BR1100514A (en) Process for the preparation of compounds derived from benzimidazoline - 2 - oxo - 1 - carboxylic acid; product / compound / composition
PE20061373A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 'N- (2-CHLORO-6-METHYLPHENIL) -2 - [[6- [4- (2-HYDROXYETHYL) -1-PIPERAZINYL] -2-METHYL-4-PYRIMIDINYL] AMINO] -5- THIAZOLCARBOXAMIDE
PE20040974A1 (en) CARBOXYL ACID AMIDE COMPOUNDS WITH ANTAGONIC EFFECT OF HCM, DRUGS THAT CONTAIN THEM AND PROCEDURES FOR THEIR PREPARATION
PE20110598A1 (en) INHIBITORS OF MITOGEN P38 ACTIVATED PROTEIN KINASE ENZYMES
KR920019750A (en) Heterocyclic Amides
PE20121314A1 (en) DERIVATIVES OF SUBSTITUTED 4-AMINOCICLOHEXANE
MX2010003950A (en) Amine derivative having npy y5 receptor antagonist activity and use thereof.
BRPI0312882B8 (en) pleuromutilin derivatives and pharmaceutical composition
PE20091579A1 (en) SUBSTITUTE SULFONAMIDE DERIVATIVES

Legal Events

Date Code Title Description
FC Refusal